风湿免疫科

订阅

MedSci主页 / 所有栏目 / 风湿免疫科

Blood：血小板特异性抗体检测的新方法

2019-10-14 QQY MedSci原创

血小板特异性抗体iPSC巨核细胞
关注

在人体内，血小板膜糖蛋白多态性具有免疫原性，是引起新生儿同种免疫性血小板减少症等疾病的重要临床免疫反应的原因。来源于携带罕见多态性个体的血小板通常难以获得，使得诊断性检测和输注匹配的血小板具有挑战性。I类HLA抗体经常出现在母体血清中，对血小板反应性同种抗体的检测带来额外的干扰。检测人血小板抗原(HPA) 3和9的同种异体抗体尤其具有挑战性，部分原因是由于位于多态氨基酸附近的细胞类型特异性聚糖的存

在人体内，血小板膜糖蛋白多态性具有免疫原性，是引起新生儿同种免疫性血小板减少症等疾病的重要临床免疫反应的原因。来源于携带罕见多态性个体的血小板通常难以获得，使得诊断性检测和输注匹配的血小板具有挑战性。I类HLA抗体经常出现在母体血清中，对血小板反应性同种抗体的检测带来额外的干扰。检测人血小板抗原(HPA) 3和9的同种异体抗体尤其具有挑战性，部分原因是由于位于多态氨基酸附近的细胞类型特异性聚糖的存在，它们共同形成了同种表位。

为了克服这些限制，研究人员生成了一系列I型HLA阴性的、O型血的、诱导多能干细胞（iPSCs），并对其进行基因编辑，使其内源性的HPA-3a同种抗原表位依次转变成HPA-3b、HPA-9a转化为HPA-9b。并使这些细胞分化成CD41+/CD42b+人巨核细胞（MKs），然后通过流式细胞仪检测可疑的抗HPA-3和HPA-9的异源抗血清，进而发现HPA-3a阳性的MKs可与HPA-3a患者的血清发生特异性反应，而HPA-3b MKs则不与HPA-3a患者的血清发生反应，而是与HPA-3b患者的血清发生特异性反应。

重要的是，表达HPA-9b的MKs与疑似抗HPA-9b的患者样本发生特异性反应，而且传统技术并不能检测出来。

在细胞表面表达完整的纯合糖蛋白同种异体抗原的特化iPSC来源的人巨核细胞，可大大提高对临床重要的、罕见的HPA特异性的同种异体抗体的检测能力。

原始出处：

Nanyan Zhang， et al.Bioengineered iPSC-derived megakaryocytes for the detection of platelet-specific patient alloantibodies.blood.2019002225. https：//doi.org/10.1182/blood.2019002225

本文系梅斯医学（MedSci）原创编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1903382, encodeId=58ea19033825e, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Sep 09 03:22:00 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899330, encodeId=3cc618993308e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 11 18:22:00 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305188, encodeId=ee4f1305188b7, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526458, encodeId=e8ce152645892, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535778, encodeId=3ad61535e781d, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
    2020-09-09 kord1982

    #新方法#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1903382, encodeId=58ea19033825e, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Sep 09 03:22:00 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899330, encodeId=3cc618993308e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 11 18:22:00 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305188, encodeId=ee4f1305188b7, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526458, encodeId=e8ce152645892, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535778, encodeId=3ad61535e781d, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
    2020-05-11 jinweidong

    #特异性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1903382, encodeId=58ea19033825e, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Sep 09 03:22:00 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899330, encodeId=3cc618993308e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 11 18:22:00 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305188, encodeId=ee4f1305188b7, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526458, encodeId=e8ce152645892, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535778, encodeId=3ad61535e781d, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
    2019-10-16 marongnuan

    #体检#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1903382, encodeId=58ea19033825e, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Sep 09 03:22:00 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899330, encodeId=3cc618993308e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 11 18:22:00 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305188, encodeId=ee4f1305188b7, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526458, encodeId=e8ce152645892, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535778, encodeId=3ad61535e781d, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
    2019-10-16 hyf032

    #特异性抗体#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1903382, encodeId=58ea19033825e, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Sep 09 03:22:00 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899330, encodeId=3cc618993308e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon May 11 18:22:00 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305188, encodeId=ee4f1305188b7, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526458, encodeId=e8ce152645892, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535778, encodeId=3ad61535e781d, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Wed Oct 16 12:22:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
    2019-10-16 tongyongming

    #抗体检测#

    0

相关资讯

Blood：嗜酸性粒细胞-血小板互作促进动脉粥样硬化和血栓的形成

临床观察发现嗜酸性粒细胞活化的标志物在动脉粥样硬化和血栓形成中升高，因此推测提嗜酸性粒细胞在心血管疾病中具有一定作用。但嗜酸性粒细胞对动脉粥样硬化斑块形成和动脉血栓形成的作用仍不明确。Marx等人在这些背景下，来研究嗜酸性粒细胞是如何通过与血小板的相互作用被招募和激活的。研究人员为嗜酸性粒细胞-血小板相互作用在动脉粥样硬化和血栓形成中的重要作用提供了证据，证明了嗜酸性粒细胞参与内皮细胞上von W

Blood：血友病的新疗法——中和PN-1

A型和B型血友病分别是因VIII 因子(FVIII)和IX 因子(FIX)缺乏使得凝血酶生成不足从而导致出血的疾病。近期新开发的血友病治疗策略不依赖凝血因子替换，而是在于中和天然抗凝蛋白。研究人员提出一种创新方法，包括靶向一种由血小板表达的天然的有效凝血酶抑制剂，称为蛋白酶nexin-1（PN-1）。通过校准的自动凝血酶生成实验，研究人员证实在短轻中度血友病患者富含血小板的血浆（PRP）中，PN-

罕见病例1例|原发性胆汁性胆管炎合并干燥综合征及免疫性血小板减少症

患者女性，52岁，因“乏力2个月，左侧季肋部疼痛伴咽痛1个月余，发现血小板减少半个月，发热5 d”于2012年11月5日入吉林大学第一医院。患者缘于2012年9月5日无明显诱因出现乏力，未系统诊治。2012年9月16日患者出现左侧季肋部疼痛伴咽痛，于2012年10月21日就诊于中日联谊医院，肺CT提示双肺肺炎，经抗炎、对症治疗后上述症状明显好转，血常规示血小板、白细胞减少，骨穿刺提示巨核细胞成熟障

Blood：缺铁促进巨核系-红系祖细胞（MEP）向巨核细胞系偏倚进展

缺铁性贫血患者血小板增多的机制尚不清楚。有这样一种假设，即低铁会促进巨核系-红系祖细胞（MEP）向巨核细胞（Mk）系偏倚进展。Xavier-Ferrucio等人在人和小鼠中证实了该假设。与野生型（WT）小鼠的MEP相比，在表现为缺铁性贫血和血小板增多症的特异性敲除跨膜丝氨酸蛋白酶6(Tmprss6-/-)小鼠的MEP中，研究人员观察到Mk偏倚、不稳定铁减少和增殖减少。骨髓移植实验显示是系统性铁缺乏

Blood：SHP2功能异常通过影响血小板的信号和功能导致努南综合征

SHP2，由PTPN11基因编码，是一种普遍存在的蛋白酪氨酸磷酸酶，是信号转导的关键调节因子。PTPN11基因的胚系突变导致SHP2的催化功能获得或丧失，分别可导致两种多器官缺陷的疾病：Noonan综合征（NS）和伴随多发雀斑的NS（NSML）。NS患者常发生出血异常，但病因尚不明确。本研究在NS/NSML患者中和携带导致这两种疾病的PTPN11突变的两种小鼠模型中研究血小板激活。NS小鼠和患者来

JAMA Neurol：双联抗血小板严重出血的特点

急性缺血性小卒中或 TIA 短期内发生缺血性卒中或其他血管事件的比例很高，发病后90天内卒中发生率为3-15%，每年为4-6%。阿司匹林能够使缺血复发的风险降低大约20%。氯吡格雷通过P2Y12通路抑制血小板聚集，也是经常使用的抗血小板药物，特别是服用阿司匹林期间复发的动脉粥样硬化事件。